Monterey Bio Acquisition Corporation (MTRY)
| Market Cap | 52.22M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -1.07M |
| Shares Out | 4.89M |
| EPS (ttm) | -0.11 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,201 |
| Open | 11.00 |
| Previous Close | 11.00 |
| Day's Range | 10.89 - 10.90 |
| 52-Week Range | 9.99 - 11.01 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About MTRY
Monterey Bio Acquisition Corporation does not have significant operations. It focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or related business combination with one or more businesses in the biotech industry. The company was formerly known as Chardan FinTech Acquisition Corp. and changed its name to Monterey Bio Acquisition Corporation in April 2021. Monterey Bio Acquisition Corporation was incorporated in 2020 and is based in New York, New York. [Read more]
Financial Performance
Financial StatementsNews
Monterey Bio Acquisition Corp. Announces Rebrand and Management Changes
NEW YORK , March 10, 2023 /PRNewswire/ -- Monterey Bio Acquisition Corporation (Nasdaq: MTRYU) today announced a rebrand to Monterey Innovation Acquisition Corp. ("Monterey Innovation" or "the Company...
Monterey Bio Acquisition Corporation Announces the Separate Trading of its Common Stock and Warrants, Commencing November 22, 2021
NEW YORK, Nov. 17, 2021 /PRNewswire/ -- Monterey Bio Acquisition Corporation (the "Company") announced today that, commencing November 22, 2021, holders of the units sold in the Company's initial publ...
Monterey Bio Acquisition Corporation Announces Closing of Initial Public Offering and Full Exercise of Underwriter's Option to Purchase Additional Units
NEW YORK, Oct. 5, 2021 /PRNewswire/ -- Monterey Bio Acquisition Corporation ("Monterey Bio" or the "Company") (Nasdaq: MTRYU) today announced the closing of its previously announced initial public off...